Insect Cell Lines Market - Growth Drivers and Challenges
Growth Drivers
- Increasing Public Interest in Genetically Modified Organisms– The genetic modification of insects has emerged as a significant topic of study as genetically modified organisms, or GMOs, are organisms that have had their genomes altered via the use of recombinant DNA technology.
- Growing Popularity of Cell-Based Therapies- Cell and gene therapies hold the potential to provide patients with life-altering medications therefore, the use of cell-based therapeutics is expanding quickly, and insect cell lines are being utilized to manufacture these therapies as they can be used as cutting-edge models with special benefits like higher efficiency and lower cost.
- Spiking Prevalence of Chronic Diseases- Insect cell lines are extensively used in the pharmaceutical sector as they aid in producing drugs and vaccines for the treatment of several chronic conditions. According to the World Health Organization (WHO), Noncommunicable diseases (NCDs) account for 41 million annual fatalities, or around 74% of all fatalities worldwide.
- Surge in Drug Development- In the early stages of drug screening, insect cell expression is common, as they provide several industrial benefits over mammalian cells, including less need for CO2, lower energy needs, and fewer biosafety requirements.
- Increasing Usage in Toxicity Screening- Insect cell cultures are used to compare the toxicities of various substances in both target organisms and non-target organisms as they are capable of mimicking certain aspects of mammalian cell responses.
- Rising Trend of Personalized Medicine- Insect cell lines are used in the production of viral vectors that have been developed to offer personalized medications that can be used for a variety of applications in medical biotechnology and biological sciences.
- Expanding Usage in Virus Research- Insect-derived cell lines offer useful resources for the controlled research of insect viruses that are spread between insects and plants.
Challenges
- High Cost of Insect Cell Lines – The cost of maintaining controlled environments is usually high as insect cell lines must be kept at 37°C and are grown at 27°C for optimum growth in a carbon dioxide-rich environment. Besides this, eliminating microbial contamination is a difficult but necessary first step in the development of an insect cell line to clean insect tissues, whereby researchers employ a variety of techniques that consume a lot of time, energy, and money.
- Competition Arising from the Presence of Other Cell-Based Technologies
- Limited Funding can Impede the Overall Efficiency of Insect Cell Lines
Insect Cell Lines Market Size and Forecast:
|
Base Year |
2025 |
|
Forecast Year |
2026-2035 |
|
CAGR |
11.5% |
|
Base Year Market Size (2025) |
USD 1.23 billion |
|
Forecast Year Market Size (2035) |
USD 3.65 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of insect cell lines is evaluated at USD 1.36 billion.
The global insect cell lines market size was worth more than USD 1.23 billion in 2025 and is poised to witness a CAGR of over 11.5%, crossing USD 3.65 billion revenue by 2035.
By 2035, the North America insect cell lines market is set to command a 35% share, impelled by increasing spending in vaccine production.
Key players in the market include Sigma-Aldrich Corporation, GE Healthcare Technologies Inc., Lonza Group, Becton, Dickinson & Company, HiMedia Laboratories LLC, Takara Bio Inc., CellGenix GmbH, Atlanta Biologicals Inc., PromoCell GmbH.